Comparative efficacy of iBGStar™ glucose meter vs. traditional glucose monitoring in improving metabolic control and compliance towards self-monitoring of blood glucose in young patients with type 1 diabetes

Introduction. It is known that Type 1 diabetes is particularly hard to control by adolescents and young adults. In this population, the mean values of glycosylated hemoglobin far exceed the recommended targets in a large majority of patients. Moreover, a major issue is compliance, both in self-monitoring of blood glucose at home and at insulin treatment

Aims. The iNewTrend study has been designed to assess whether in a type 1 diabetes population aged 14-24 y.o., not compliants with self-monitoring blood glucose and not well controlled from a metabolic point of view, the use of technology (i.e. a next-generation blood glucose meter – iBGStar – linked with a smartphone) could improve adherence to treatment, clinical results and acceptance of the disease

Type of study. Randomized, controlled parallel group (1: 1), multi-center study

Population. 181 patients with type 1 diabetes treated with multiple injections of insulin, HbA1c> 8.0%, not compliants with home self-monitoring of blood glucose (<30% of the measurements prescribed by a doctor)

Centers. 21 Italian diabetes centers

Promoter. Sanofi SpA, Italy

Funding. Sanofi SpA, Italy

Status. Study completed


  1. Di Bartolo P, Nicolucci A, Cherubini V, Iafusco D, Scardapane M, Rossi MC. Young patients with type 1 diabetes poorly controlled and poorly compliant with self-monitoring of blood glucose: can technology help? Results of the i-NewTrend randomized clinical trial. Acta Diabetol 2017; 54: 393-402.